This is a routine insider ownership filing with no immediate trading signal. Monitor for stockholder approval of the preferred stock conversion, which would trigger significant dilution and potential insider selling. The conversion cap limits near-term dilution but the large potential share count warrants attention.
Price Chart
Executive Summary
Patrick J. Crutcher filed a Form 3 initial statement of beneficial ownership, disclosing 518,331 shares of voting common stock and 463,452 shares of non-voting convertible preferred stock. The preferred stock converts into 61 common shares per preferred share upon stockholder approval, subject to a 4.9%-19.9% beneficial ownership cap, representing significant potential dilution upon conversion.
Key Facts
- Patrick J. Crutcher filed Form 3 as a new reporting owner of Jasper Therapeutics.
- Crutcher directly owns 518,331 shares of voting common stock.
- Crutcher directly owns 463,452 shares of non-voting convertible preferred stock.
- Each preferred share converts into 61 shares of voting common stock upon stockholder approval, subject to a 4.9%-19.9% beneficial ownership limitation.
- The preferred stock has no expiration date.
Financial Impact
No financial figures disclosed. Potential conversion of preferred shares could result in up to 28,270,572 additional common shares (463,452 × 61), subject to ownership cap.
Risk Factors
- Potential dilution from conversion of 463,452 preferred shares into up to 28.3 million common shares.
- Insider may sell shares post-conversion, creating selling pressure.
- Conversion is contingent on stockholder approval and ownership cap, creating uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001213900-26-079762 |
| Document: 0001213900-26-079762-index.html | 0001213900-26-079762 |
| Document: 0001213900-26-079762.txt | 0001213900-26-079762 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | SC TO-I/A | $0.5100 | awaiting T+5 | — | $0.5050 (−0.98%) |
Oct 20, 2026 6d ago | DEF 14A | $0.4999 | awaiting T+5 | — | $0.5050 (+1.02%) |
Oct 15, 2026 11d ago | 8-K | $0.5321 $0.4956 | ▼ −6.86% | ▼ −5.85% | $0.5050 (−5.09%) |
Oct 15, 2026 11d ago | Press Release | $0.5320 $0.4960 | ▲ +6.77% | ▲ +5.75% | $0.5050 (+5.08%) |
Oct 14, 2026 12d ago | S-3 | $0.5321 $0.4956 | ▲ +6.86% | ▲ +5.85% | $0.5050 (+5.09%) |
Oct 7, 2026 19d ago | 8-K | $0.5697 $0.5010 | ▼ −12.06% | ▼ −11.08% | $0.5050 (−11.36%) |
Oct 7, 2026 19d ago | SC TO-I | $0.5697 $0.5010 | ▼ −12.06% | ▼ −11.08% | $0.5050 (−11.36%) |
Sep 24, 2026 4w ago | 25-NSE | $0.6091 $0.5652 | ▲ +7.21% | ▲ +6.99% | $0.5050 (+17.09%) |
Aug 14, 2026 10w ago | Press Release | $0.7901 $0.7160 | ▼ −9.38% | ▼ −8.01% | $0.5050 (−36.08%) |
Jul 31, 2026 12w ago | 8-K | $0.6300 $0.7095 | ▲ +12.62% | ▲ +9.11% | $0.5050 (−19.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers